Background {#Sec1}
==========

The evolution of delivery techniques in external beam radiotherapy has paralleled the need for online image guidance, aiming at enhanced conformal treatments \[[@CR1]\]. The use of technologies such as IMRT (intensity modulated radiotherapy) \[[@CR2]\] and VMAT (volumetric modulated arc therapy) \[[@CR3]\] has increased the necessity of volumetric imaging as a way to measure and handle uncertainties. In recent years, cone beam CT (CBCT) has progressively become the standard approach to implement IGRT (image-guided radiotherapy) \[[@CR4], [@CR5]\]. Nonetheless, CBCT exhibits intrinsic limitations, due to suboptimal image quality, poor soft tissue contrast and the additional imaging dose. Furthermore, the use of CBCT to manage specific uncertainties, such as tumor motion, is not established and may be questioned when considering the inherent shortcomings \[[@CR6], [@CR7]\].

For the above-mentioned reasons, magnetic resonance imaging (MRI) has been extensively explored as an alternative to implement IGRT, with significant research and commercial efforts to integrate MRI in treatment delivery devices \[[@CR8]\]. MRI has been used for a long time in radiotherapy, with the first application in intracranial radiosurgery published in the mid-1980s, showing the ability to visualize post irradiation changes \[[@CR9]\]. Since those pioneering days, MRI has steadily been utilized for more and more cancer sites. The use of MRI for treatment planning simulation in radiation therapy is reported since the early days \[[@CR10]\], with first attempts to plan directly on MR images in the 1990s \[[@CR11]\]. The increased need for radiotherapy-specific products drove the market for dedicated MRI simulators with flat couch tops, dedicated coils and MRI-compatible immobilization systems.

The increased presence of MRI in radiotherapy, in parallel with the rapid adoption of X-ray and other image guidance methods, spurred the integration of MRI with radiation therapy systems, as a way to implement MRI-based IGRT. An overview of MR-guided radiotherapy (MRgRT) approaches utilizing a linac is shown in Table [1](#Tab1){ref-type="table"}: each of them features different characteristics in terms of magnetic field strength, beam type and energy, and the orientation of the radiation beam and the magnetic field (perpendicular or inline). Among these, the only two commercial systems currently available are the ViewRay MRIdian and the Elekta Unity. Table 1An overview of linac-based MRgRT approaches. The third column includes information on the field strength and orientation of the magnetic field relative to the radiation beam (perpendicular/inline)Company/institutionCommercial?MRI and beam specificationReferenceViewRayYes0.35 T split bore magnet, 6 MV beam (originally ^60^Co), perpendicular\[[@CR12]\]ElektaYes1.5 T closed bore magnet, 7 MV beam, perpendicular\[[@CR13]\]University of AlbertaUnder development0.5 T biplanar magnet, 4 and 6 MV beams, inline/perpendicular\[[@CR14]\]Australian MR-linac programNo1.0 T split bore magnet, 4 and 6 MV beams, inline/perpendicular\[[@CR15]\]SiemensNo0.5 T closed bore magnet, 6 MV linac inside bore, perpendicularPatent no.US 8,958,864 B2Princess Margaret HospitalNoSeparated 1.5 T closed bore magnet on rails and a conventional multi-energy linear accelerator (offline MRgRT)\[[@CR16]\]

MRgRT offers a new paradigm to address delivery uncertainties \[[@CR12], [@CR17]\]. While in conventional external beam radiotherapy the patient is positioned to suit a static plan, MRgRT enables adaptation of the plan to optimize dose coverage for the actual patient's anatomy of the day. Key in this new paradigm is the superb soft tissue contrast of MRI which allows direct visualization of the tumor and the organs-at-risk (OAR) \[[@CR18]\]. As an additional benefit, there is no radiation dose burden with MR imaging, which allows for frequent verification. Current advances provide the technological framework to implement IGRT protocols at optimal soft tissue contrast and absence of imaging dose, relying on dedicated procedures for immobilization and imaging. Such imaging capabilities offer the potential for treatment adaptation and quantitative measurement for treatment monitoring and tailoring. Despite such advantages, potential weaknesses exist \[[@CR19]\], which require specific medical physics developments to make the most of technological advances in MRI guidance. The intrinsic lack of electron density information, along with the presence of a static magnetic field during treatment delivery, require sophisticated dose calculation methods and dedicated quality assurance (QA) procedures. In addition, MR imaging is prone to spatial distortions and sequence-dependent effects, especially in presence of motion, thus requiring extensive measurements and modeling for accurate MRgRT implementation.

This review will cover the key aspects underlying the necessary physics developments, as a way to summarize the potential and pitfalls of MRgRT. More specifically, this review will address the topics of MR imaging, dose measurement and calculation in the presence of a magnetic field, MR-guided treatment adaptation, as well as QA aspects.

MR imaging {#Sec2}
==========

MR-linacs and in-room MRI scanners allow dose-free extended imaging directly before or during treatment (online) with the patient in treatment position. An MRgRT fraction starts with a so called pre-beam phase, where a first in-room MR image with a relatively large field-of-view (FOV) is acquired to visualize all relevant structures, including OAR and target contours.

Imaging of the static anatomy {#Sec3}
-----------------------------

Pre-beam imaging is usually performed using 3D imaging protocols, relying on either stacked 2D slices or native 3D MR acquisition sequences. The former approach has been reported for low-field MR-linacs using a bSSFP (balanced Steady State Free Precession) sequence \[[@CR20]\], whereas the latter has been applied for 1.5 T MR-linacs relying on 3D spoiled gradient echo sequences, such as \[[@CR17], [@CR21]\], or 3D T2-weighted Turbo Spin Echo (TSE) scans. Native 3D MR acquisition has certain distinct advantages, as it can potentially minimize slice distortions that occur in 2D imaging due to B~0~ inhomogeneity. Furthermore, the 3D isotropic resolution facilitates the verification of the organ contours in all three planes, which might also increase the accuracy of the patient alignment process. Potential optimization in 3D imaging is feasible by the use of 3D T2-weighted TSE imaging, which is characterized by a relatively long echo train with refocusing control, where the flip angle is constantly modulated to find an optimal balance between contrast and sufficient signal during the acquisition of the central k-space lines \[[@CR22]\]. Examples of images acquired with low-field and high-field MR-linacs are depicted in Fig. [1](#Fig1){ref-type="fig"}. Fig. 1Sample pre-beam images acquired on a 1.5 T MR-linac (3D SPGR sequence, left panel) and on a 0.35 T device (bSSFP sequence, right panel). Adapted and reprinted with permission from \[[@CR20], [@CR23]\]

Imaging for motion monitoring {#Sec4}
-----------------------------

In the case of sites affected by respiratory motion, pre-beam imaging in today's clinical routine is typically performed in breath-hold, utilizing standard 3D sequences. Pre-treatment 4D-MRI might allow for an improved assessment of inter-fractional motion changes \[[@CR24], [@CR25]\], but is currently not offered on clinical systems \[[@CR19]\], despite the high interest in the development of respiratory-correlated 4D-MRI (rc-4D-MRI) for MRgRT \[[@CR26]\]. In rc-4D-MRI, images are created by retrospective sorting or prospective acquisition in image- or k-space domain acquired over several breathing cycles to reconstruct, typically, one average breathing cycle. Fast imaging sequences such as bSSFP, T2-weighted TSE and spoiled gradient echo are most often used for this purpose \[[@CR26]\]. The in-plane resolution of the reconstructed 4D-MRI is typically between 1-2 mm with slice thicknesses of around 5 mm for 2D read-out sequences \[[@CR26]\] and voxel sizes down to 1.2 × 1.2 × 1.6 mm^3^ \[[@CR27]\] for 3D read-out sequences acquired with a diagnostic 1.5 T scanner. The spatial resolution and number of reconstructed breathing phases determines the acquisition time which is in the order of several minutes \[[@CR26]\]. Adaptive treatment planning based on rc-4D-MRI could reduce uncertainties compared to today's clinical standard workflow based on four-dimensional CT \[[@CR7], [@CR28]\]. The high-quality images provided by rc-4D-MRI could reduce delineation uncertainties and allow for improved internal target volume \[[@CR28]\], mid-position \[[@CR29]\] and gating window \[[@CR26]\] definitions. As described in the next section, rc-4D-MRI can provide training data for global motion models \[[@CR30]\] that could be applied during or after irradiation. Challenges associated with rc-4D-MRI include geometric distortions, long acquisition times \[[@CR31]\] and 4D image validation without ground truth data \[[@CR24], [@CR26]\]. Furthermore, most rc-4D-MRI methods cannot accurately assess cycle-to-cycle variations and baseline shifts, as typically only one breathing cycle is reconstructed \[[@CR25]\].

During irradiation, the beam-on imaging capabilities of today's clinical MR-linac systems allow real-time intra-fractional monitoring of tumor and OAR motion \[[@CR12], [@CR32], [@CR33]\]. Fast 2D cine MRI sequences like bSSFP \[[@CR34]\] or spoiled gradient echo \[[@CR35]\] achieve acquisition times down to 150 ms \[[@CR36]\]. The imaging data is nowadays routinely used for gated treatments of tumors in thoracic and abdominal organs, and first clinical studies have been published \[[@CR37]--[@CR40]\]. These studies used the vendor's 2D cine bSSFP MRI sequence, acquiring a single sagittal slice with an in-plane resolution of 3.5 × 3.5 mm^2^ and slice thicknesses between 5 and 10 mm at a frame rate of 4 Hz \[[@CR12], [@CR32], [@CR41]\].

Research on cine MRI for MRgRT has been focused on the optimization of several sequence parameters. The impact of the spatial resolution on the target tracking accuracy has been investigated by several groups \[[@CR35], [@CR42], [@CR43]\]. Robustness of target tracking algorithms and registrations against different geometrical sequence parameters led to the conclusion that only moderate accuracy gains are to be expected from increased imaging resolution with respect to today's clinical sequences \[[@CR42], [@CR43]\]. Better image resolution could still be desirable to improve visibility for smaller lesions, although neighbor structures can be exploited to track reliably. At the same time, different strategies to accelerate image acquisition and reconstruction are investigated in the literature. These include partial Fourier acquisition, different k-space read-out strategies and the use of deep learning to shorten reconstruction times \[[@CR24], [@CR26]\]. Parallel imaging capabilities of today's clinical MR-linacs are also still constrained by the available hardware \[[@CR25], [@CR41], [@CR44]\]. The development of faster sequences could enable motion monitoring of the heart, which could be either used to achieve heart dose reduction \[[@CR45]\] or to guide cardiac ablation interventions with MR-linacs in the future \[[@CR46], [@CR47]\].

The development of new sequences with different imaging contrasts might facilitate image registration and motion tracking and needs to be further investigated \[[@CR43]\]. In clinical practice as well as in research studies, the sagittal slice orientation has been most often used for cine MRI \[[@CR24], [@CR32]\], but as MR imaging allows for arbitrary slice orientations, the impact of different orientations on the tumor tracking accuracy has been evaluated \[[@CR25], [@CR43]\]. No consensus has been found yet \[[@CR44]\], but the ideal slice orientation and position might be entity- and patient-specific \[[@CR43]\] and depend on the beam angle \[[@CR48]\].

As out-of-plane motion can occur when a single 2D slice is used, the acquisition of several parallel slices \[[@CR12], [@CR49]\] or the interleaved \[[@CR50]--[@CR53]\] or simultaneous \[[@CR54], [@CR55]\] acquisition of orthogonal slices has been investigated. Acquiring imaging data from different orientations could indeed enable the real-time reconstruction of the anatomy in 3D \[[@CR53]\]. Based on single or multiple cine MRI slices, the temporally resolved 3D motion of the whole anatomy of the patient can be estimated by global motion models \[[@CR30], [@CR56], [@CR57]\]. These models use temporally resolved 1D or 2D surrogate signals as inputs in combination with rc-4D-MRI data that could be acquired in the pre-treatment imaging phase \[[@CR24]\]. Up to date, these motion models have not been clinically used for MRgRT and validation with ground truth data remains challenging \[[@CR30], [@CR58]\]. Beyond the use of cine MRI for gating, the availability of time-resolved volumetric imaging acquired during treatment will give opportunity to guide multi-leaf collimator (MLC)-tracking \[[@CR59]\] and to perform post-beam dose accumulation \[[@CR26]\]. This information could be used for real-time image-guided adaptive radiotherapy (IGART) \[[@CR60]\] and improved dose-response modelling.

The development of real-time 4D-MRI (rt-4D-MRI) \[[@CR26], [@CR61]--[@CR63]\] with sufficient spatio-temporal resolution would be desirable both for pre-treatment inter-fractional motion characterization as well as for real-time beam-on guidance \[[@CR24]\]. Considering the recent advances in imaging and reconstruction acceleration \[[@CR26]\] and the observation that coarse spatial resolution could yield acceptable localization errors for real-time MRgRT \[[@CR42]\], rt-4D-MRI is expected to play an increasingly important role in MRgRT in the future \[[@CR26]\]. As for rc-4D-MRI, geometric distortions and image artifacts of 2D cine MRI and rt-4D-MRI sequences need to be accounted for \[[@CR64], [@CR65]\], imaging latencies have to be kept as low as possible \[[@CR66]\] and dedicated QA for gating and tracking are needed.

Quantitative imaging {#Sec5}
--------------------

In radiotherapy-related applications, quantitative MR imaging (qMRI) has been considered to support treatment planning and to implement MRI-only treatment workflows \[[@CR67], [@CR68]\]. Specifically, qMRI refers to the objective measurement of a biophysical property of the examined tissue that can be expressed in physical units \[[@CR69], [@CR70]\]. Recent efforts in improving qMRI robustness \[[@CR69], [@CR71]\] are mainly driven by the clinical need for reliable imaging of biomarkers in oncology \[[@CR72]\]. This is not necessarily related to MRgRT, whose clinical implementation is still at an early stage, although qMRI principles could further leverage the importance of MR guidance in the field. Along with opportunities, qMRI also brings new challenges \[[@CR73]\] to established clinical practices which may need to be updated; considering for example imaging protocols harmonization, quality control and assurance procedures, staff expertise, data handling and software verification \[[@CR70], [@CR74]--[@CR76]\].

Among qMRI techniques, functional imaging can play a relevant role in MR-guided workflows \[[@CR77]\] and its use complemented with that of anatomical acquisition is being explored to provide multi-parametric analyses \[[@CR78], [@CR79]\]. Specifically for functional qMRI protocols, dynamic contrast enhanced and diffusion weighted MRI have been widely explored \[[@CR80]--[@CR82]\] due to their sensitivity to vasculature architecture \[[@CR83]\] and tissue structure \[[@CR76], [@CR84]\], respectively. These sequences could improve any stage of the radiotherapy workflow \[[@CR75], [@CR85], [@CR86]\]: from diagnosis and patient stratification \[[@CR87], [@CR88]\], through contouring and dose optimization \[[@CR89], [@CR90]\], to treatment monitoring and response assessment \[[@CR83], [@CR91], [@CR92]\]. Initial clinical experience for diffusion weighted MRI has been reported for the low field MR-linac \[[@CR93]\]. In addition, T1 and T2 mapping protocols, obtained through relaxometry \[[@CR94]\], can provide quantitative tissue mapping at high spatial resolution. Together with proton density MR, they have been used to improve automatic contouring in radiotherapy \[[@CR95]\], to detect early radiation-induced effects \[[@CR79]\] or to differentiate recurrent tumors from benign tissue, when coupled to functional qMRI \[[@CR78]\].

Nevertheless, in order to be reliably employed in the clinical routine, qMRI must undergo both technical and biological/clinical validation \[[@CR96]\]. Technical validation in qMRI entails testing for accuracy, repeatability and reproducibility of the underlying physical measurement, both over time and across sites \[[@CR72], [@CR97]\]. Technical tolerances related to hardware components should be first identified and then quantified through physical phantoms, by following the available standardized procedures or guidelines and recommendations \[[@CR71], [@CR98]--[@CR101]\]. These latter are being developed and updated by several bodies \[[@CR69]\], although a global procedure is yet to be found \[[@CR67]\]. At the same time, the analysis of the MR signal itself should be carried out through robust software. Computational methods employed to derive clinically useful quantitative parameters from MRI (i.e., imaging biomarkers \[[@CR102]\]) should be validated and their quality assessed by making use of phantoms and reliable open-source tools \[[@CR71], [@CR99], [@CR103], [@CR104]\]. On the other hand, the quantification pertaining the biological/clinical validation relies on the evaluation of the relationship between imaging and the underlying biophysical parameter of interest. This relationship must be proven to be quantitative, i.e., accurate, repeatable and reproducible, as well as relevant, specific and consistent \[[@CR96]\]. The whole process of validation for qMRI biomarkers is shown in Fig. [2](#Fig2){ref-type="fig"}. Overall, quantifying technical and biological tolerances associated to any qMRI protocol is fundamental for computing the minimum detectable variation in the specific qMRI parameter that could, once clinically validated, distinguish underlying pathophysiological changes from measurement uncertainties \[[@CR71]\]. Fig. 2Flowchart for validated use of qMRI biomarkers, with representative images at each step. Adapted and reproduced with permission from \[[@CR69], [@CR78], [@CR80], [@CR89]\]

The above-mentioned aspects will surely require more resources and optimization efforts, but only by tackling all the variabilities and error sources in the quantitative framework, qMRI can represent a reliable input for MR-guided adaptive radiotherapy.

Dose measurements and calculations in the presence of magnetic fields {#Sec6}
=====================================================================

Dose measurements {#Sec7}
-----------------

Reference dosimetry at MRgRT systems requires modifying the TG51 guidelines \[[@CR105]\] from the American Association of Physicists in Medicine (AAPM), or national equivalent (TRS 398 or other), to account for the effects of the magnetic field on i) the depth dose distribution, ii) the ion chamber response, and iii) the impact of the machine design on the definition of reference conditions, such as the source-to-surface distance (SSD). Both i) and ii) are directly related to curved electron paths \[[@CR106], [@CR107]\]. In the case of i), these cause an effective reduction of secondary electron range projected along the beam direction, which leads to an upstream shift of both the maximum dose (*d*~*max*~) and the depth dose curve (see Fig. [1](#Fig1){ref-type="fig"} in \[[@CR108]\]), thus reducing the dose at the point of measurement by 0.5%/0.3% at 1.5 T/1 T \[[@CR109], [@CR110]\]. This means that when asserting the impact on chamber response, care must be taken to account for i), if measuring with and without a magnetic field, and when estimating beam quality specifiers. The change in chamber response ii) is described in the first order by variations in electron trajectories through the sensitive volume; this entails that chamber geometry, orientation and magnetic field strength have a large impact on response \[[@CR107]--[@CR113]\]. However, to fully explain response variations, for example by Monte Carlo modelling, it is necessary to additionally account for the gas volume where charge is collected by the guard electrode \[[@CR110], [@CR113]\]. Finite element modelling of electric field lines coupled to Monte Carlo simulation has been shown by \[[@CR114]\] to reproduce well chamber response to different field strengths. In practice, chamber response is much less affected when the cylindrical chamber's axis is parallel to the magnetic field and the latter is perpendicular to the beam. Beam quality specifiers should also be carefully considered in MRgRT systems. *%dd* (10)~*x*~ may be problematic due to non-reference SSDs and the above-mentioned shift in *d*~*max*~; thus most publications recommend the use of $\documentclass[12pt]{minimal}
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A few modifications to TG51 have been published which allow reference dosimetry at MRgRT systems. O'Brien et al. \[[@CR109]\] pioneered the use of a correction to *N*~*D,w*~ in the presence of magnetic fields determined by Monte Carlo simulation of ion chambers. Malkov and Rogers \[[@CR115]\] compared the introduction of a correction to *N*~*D,w*~ accounting for both changes in beam quality and presence of the magnetic field, versus an additional correction related only to magnetic field effects. They also use Monte Carlo simulation of ion chambers. Van Asselen et al. \[[@CR108]\] proposed to reduce the burden on chamber modelling, which may be desirable given the subtleties of dead volume computation, by proposing a with/without magnetic field measurement-based approach where Monte Carlo simulation is used to determine the change of dose from i) instead. It may however not be feasible for every institution to have the possibility of performing measurements with and without magnetic field, hence the need for consensus values on chamber correction factors for standard ion chamber models in the literature. While the challenges listed above require careful attention, most authors agree that they are not insurmountable and that reference dosimetry is feasible. Particularly with the parallel orientation described above, corrections for chamber response are understood to be well within 1% of unity. Official guidelines for absolute dosimetry are however not currently established, placing a burden on early adopters. Primary standards labs and research groups have also recently worked towards MR-compatible water calorimeters \[[@CR116]--[@CR118]\] and graphite \[[@CR118], [@CR119]\] calorimeters. This allows the direct measurement of ion chamber correction factors \[[@CR120]\], which should soon lead to additional literature.

For relative dosimetry, care must be taken to account for a shift of the effective point of measurement (EPOM). O'Brien et al. \[[@CR121]\] showed, using measurements with and without magnetic field, that at 1.5 T a Farmer chamber exhibits a different EPOM than at 0 T, and recommend using 0.3 × R~cav~. In addition to the depth displacement of the EPOM, lateral displacements are also present, and are detector-dependent. It is expected that at 0.35 T the EPOM displacement is reduced, however, thus far this has not been reported in the literature. Looe et al. \[[@CR122]\] used Monte Carlo simulations to show that such shifts are inversely proportional to the detector density.

Commercial cylindrical diode arrays have also been tested at 1.5 T, highlighting a 1.5% maximum dose deviation compared to a standard delivery device \[[@CR123]\]. Preliminary studies on the use of thermoluminescent dosimeters have been published \[[@CR124], [@CR125]\]. For a 1.5 T field, Matthis et al. reported no difference within a 5% criterion, while Wen et al. reported directional variations of up to 2.3%. Steinmann et al. performed a study of both 0.35 T and 1.5 T systems in anthropomorphic phantoms and have reported deviations of -0.3% and 1.6%, respectively \[[@CR126]\].

Due to growing interest in 3D dosimetric detectors, gel and plastic-based solutions have been tested in magnetic fields \[[@CR127]--[@CR129]\]. Polymeric gels have been shown to be comparable to Gafchromic films for checking the isocenter accuracy \[[@CR128]\]. Overall, 3D dosimeters for dose response in a magnetic field exhibited a maximum difference of 1.6% in a comparison study \[[@CR129]\]. The degradation of plastic 3D dosimeters over time was also quantified, reporting changes in optical density of around 5% per day, which did not impact on IMRT verification relying on AAPM TG 119 \[[@CR130], [@CR131]\]. Also, Cherenkov imaging has been tested to acquire high-resolution real-time dosimetric data, though limited to a 2D projection of the 3D dose cube \[[@CR132]\].

Dose calculations {#Sec8}
-----------------

Dose calculation engines designed for treatment planning at MRgRT systems should account for the impact of the magnetic field on the dose from electrons, and be sufficiently fast not to hinder online plan adaptation procedures. The magnetic field will reduce the build-up length, cause a shifted and asymmetric penumbra as well as the electron return effect and may increase skin dose away from the field by deflecting contaminating electrons \[[@CR106], [@CR133]--[@CR137]\]. While Monte Carlo codes such as Geant4, PENELOPE, MCNP and EGSnrc are well benchmarked for conventional radiotherapy, and offer magnetic field capabilities, their emphasis on accuracy renders them unsuitable for treatment planning due to long calculation times. Algorithms making approximations or using variance reduction techniques have thus been developed as an alternative, and been used in conventional treatment planning systems \[[@CR138]--[@CR144]\]. For the 1.5 T Elekta MR-linac, GPUMCD, a GPU-based Monte Carlo engine, has been included in the Monaco TPS and shown to allow fast optimization \[[@CR143]\]. GPUMCD uses four tissue classes (air, lung, soft tissue and bone) and a CT number to electron density conversion. For the 0.35 T ViewRay system, the KMC engine has been developed as an improvement to VMC \[[@CR145]--[@CR147]\] to achieve fast calculation speeds. Studies have also been published where research dose calculation engines have been developed and used to compare to the clinical implementations provided by the vendors \[[@CR148], [@CR149]\]. Wang et al. developed a GPU-based Monte Carlo simulation platform for the ViewRay MRIdian using ^60^Co \[[@CR148]\]. The platform was based on a translation of *penelope* from Fortran to C++, and was called *gpenelope*. They reported calculations times improved by a factor of 152 compared to Penelope, and pass rates for KMC vs gpenelope of 99.1%±0.6% (2%/2 mm). Good agreement with measurements was obtained. Ahmad et al. compared GPUMCD to Geant4 in the presence and absence of a 1.5 T magnetic field \[[@CR149]\]. They however did not model the source explicitly and used a point source with a 7 MV spectrum instead. For various combinations of heterogeneities good agreement was observed between Geant4 and GPUMCD.

MR-guided treatment adaptation {#Sec9}
==============================

In MRgRT, the baseline treatment plan, optimized based on planning CT and MRI data, can be adapted to the daily anatomical-pathological situation in treatment position as seen on the acquired in-room MRI. The main aim of treatment plan adaptation is to minimize the impact of inter-fractional changes. This enables tighter conformation of the applied dose to the target volume, i.e., practically the use of reduced PTV margins, with optimal sparing of close-by OAR. During irradiation, further measures can be taken to also address intra-fractional changes. The most important steps are outlined in the following.

Adaptation for inter-fractional changes {#Sec10}
---------------------------------------

On-table re-optimization of the treatment plan generally requires an up-to-date 3D relative electron density image of the patient in treatment position, the corresponding delineation of targets and nearby OAR, fast dose calculation, plan optimization and finally a means to perform fast QA tests on the updated plan. An exemplary workflow is illustrated in Fig. [3](#Fig3){ref-type="fig"}. Fig. 3Illustration of an online adaptive MRgRT workflow. The in-room MRI and a pre-treatment CT are used for delineation and pseudo-CT generation. Based on these data, a new treatment plan is optimized (in this case fully automatic). An independent dose calculation is used for online plan QA. In parallel, a final position verification (PV) MRI scan is acquired and eventually the treatment is applied. Reprinted with permission from \[[@CR17]\]

The typical online adaptive MRgRT workflow starts with patient immobilization and 3D in-room imaging, followed by accurate patient alignment using image fusion. When the patient is positioned correctly, the initial treatment plan is re-calculated on the daily anatomy to infer the dose of the day, which is then used for deciding whether the treatment has to be adapted.

For dose calculation, a 3D electron density map is obtained from pseudo-CT generation methods, typically employing similar methods as developed for PET-MR attenuation correction. While there is a variety of methods for pseudo-CT generation discussed in the literature \[[@CR150]\], currently clinically implemented methods rely either directly on deformable image registration (DIR) of a pre-treatment CT \[[@CR151]\] or on a combination of DIR and bulk assignment \[[@CR21]\]. The reliance on DIR may lead to challenges when the planning CT and in-room MRI exhibit markedly different anatomy. Thus deep learning-based techniques play an increasingly important role for pseudo-CT generation, but are not in clinical use yet \[[@CR152]--[@CR155]\].

Regarding the dose calculation itself, a fast dose engine capable of incorporating magnetic fields is crucial, since plan evaluation and potential re-optimization have to be performed with the patient already in treatment position. Thus, as described above, fast Monte Carlo-based methods are employed for dose calculation \[[@CR144], [@CR148]\]

For clinically evaluating the obtained daily dose distribution (and also for potential treatment re-optimization later in the workflow) up-to-date delineation of the target volume and OAR is required. A clear advantage of MRgRT over conventional (CBCT-based) approaches for this task is the superior soft tissue contrast. In clinical online adaptive MRgRT workflows, contour suggestions are obtained from the same DIR used for pseudo-CT generation, followed by manual adaptation by an expert. Since this is still a time-consuming task, typically only a region encompassing the target volume by 2 cm \[[@CR21]\] or 3 cm \[[@CR151]\] is considered for manual correction due to time constraints. A potential solution overcoming limitations related to DIR, is the use of deep convolutional neural networks that have raised considerable attention for medical image segmentation and recently been applied to in-room MRI data \[[@CR156]--[@CR158]\]. However, clinical certification of such algorithms will be an important hurdle to be cleared in the future.

Considering the daily dose distribution and the updated delineations, a decision whether the treatment plan has to be adapted can be made by the clinical staff, e.g., by inferring deviations in the clinical goals defined at the planning stage. For treatment adaptation, several options exist in the current workflow: for the certified low field MR-linac, adaptation of the table position (3D translation) or full re-optimization are feasible, whereas for the certified high field MR-linac, no table correction is feasible, but the plan has to be adapted instead. Besides full re-optimization of the plan, which might be time-consuming, segment alignment to account for simple target displacement or re-optimization of the segment weights only (since displacing segments in flattening filter free beams may alter the dose rate) are potential alternatives \[[@CR159]\]. The re-optimization of the daily treatment plan will take place in an online fashion, why speed, not only in dose calculation, but also in plan optimization is of utmost importance. For this, also auto-planning, promising high and consistent plan quality, might play an increasingly important role in the future \[[@CR17]\].

Before applying the adapted plan to the patient, QA of the novel plan has to be performed. For this, independent dose calculations are being performed prior to delivery of the adapted plan and the calculated dose is compared to the prediction of the planning system. More details can be found in the following QA section.

Adaptation for intra-fractional changes {#Sec11}
---------------------------------------

In current clinical practice, intra-fractional organ motion related to breathing is considered by performing gated beam delivery, potentially in combination with breath-hold techniques to enhance beam-on time \[[@CR32], [@CR39]\]. A main advantage in MRgRT is that for gating, the tumor can be directly visualized and tracked using 2D+t cine MRI, as described above. Whenever the delineated tumor moves out of a user-defined gating area, the beam is stopped. While this minimizes the impact of tumor motion on the delivered dose distribution, it can considerably prolong the treatment. Thus, researchers are looking into options for performing real-time treatment adaptation during irradiation to compensate for intra-fractional motion. For this, the tumor could either be continuously trailed during beam delivery \[[@CR160]\], or the dose applied up to a certain time point during irradiation could be accumulated (assuming continuous 3D motion monitoring) and used for optimizing the remaining dose to be applied in that treatment fraction \[[@CR29], [@CR60]\].

Quality assurance {#Sec12}
=================

In the early clinical adoption phase of MRgRT, QA plays an integral role, but dedicated guidelines and protocols are still missing, often leading to the development of diverse in-house solutions. Thus, early adopters of MRgRT report that sharing experience in QA is desirable to shorten the time needed to reach significant clinical use \[[@CR161]\]. In general, a risk assessment based on Failure Mode and Effects Analysis is suggested for setting up required QA procedures. Specific challenges relate to the fact that QA protocols have to be MR-compatible and that proper QA has to carefully address all aspects of MRgRT. These encompass treatment delivery and MRI QA, end-to-end tests, patient-specific QA and QA of the online adaptive workflow.

Treatment delivery and MRI QA {#Sec13}
-----------------------------

As early clinical experience in MRgRT is from the ^60^Co system with an integrated 0.35 T MRI \[[@CR12]\], the definition of QA procedures relies mostly on that know-how, where online adaptive MRgRT is first documented \[[@CR162]\]. Initial procedures for commissioning intensity modulated plan delivery in MRgRT are reported in \[[@CR131], [@CR163]\], where the IMRT delivery performance is benchmarked following the recommendations of the AAPM Task Group 119 for IMRT commissioning. In general, characterization and QA of the machine specific beam parameters (percentage depth dose, lateral profiles, flatness, symmetry, output factor, isocenter accuracy and others) closely follow the standard protocol for conventional step-and-shoot IMRT. The same holds true for the obligatory quality checks of the MLC performance (e.g., picket fence test). However, the specific MRgRT setting and presence of the magnetic field have to be considered \[[@CR164], [@CR165]\]: typically, conventional water phantoms do not fit in the bore of clinical MRI-linacs and stepping motors are not MR-compatible. Moreover, the orientation of ionization chambers and the corresponding correction factors have to be carefully considered.

On the imaging side, standard quality checks for, among others, B-field homogeneity or signal-to-noise ratio, using conventional MRI QA phantoms (ACR phantom) are crucial. In addition, a critical issue in MRgRT QA is the quantification of spatial distortions induced by MRI \[[@CR65]\]. These can be divided into system-dependent and patient-dependent factors \[[@CR166]\]. System-dependent distortions are mainly due to static field inhomogeneities and non-linearity effects of the applied magnetic field gradients, where the latter is the dominant effect \[[@CR166]\]. Patient-dependent causes include variations in magnetic susceptibility of different tissues \[[@CR167]\] and chemical shift, which accounts for intra-tissue deviations due to the surrounding chemical environment \[[@CR168]\]. System-related factors, representing the larger uncertainty, are typically handled relying on vendor-specific distortion corrections algorithms, whose performance is dependent on the applied MR imaging sequence and requires verification with geometrical phantoms \[[@CR169]\]. Susceptibility induced distortions are more difficult to tackle, as they are strictly dependent on the patient being imaged \[[@CR166]\]. It has been shown that major effects are found at the air-tissue interface, with a clear dependency on the magnetic field and gradient strength \[[@CR166]\]. Susceptibility effects can be measured using specialized MRI sequences \[[@CR170]\] or simulated from an anatomical image, which requires the prior determination of volume susceptibilities of different tissues \[[@CR171]\]. Conversely, chemical shift artifacts, mostly visible at the interface of fat regions, can be conveniently reduced by using a wider receiver bandwidth, a smaller FOV, or applying fat saturation techniques in the MR imaging sequence \[[@CR166]\].

Finally, yet importantly, dedicated tests ensuring flawless parallel usage of imaging and treatment units have to be performed. Similar to conventional radiotherapy, these tests include verification of accurately aligned imaging and treatment isocenters using dedicated MR-compatible phantoms \[[@CR172]\], but also potential system interferences between linac and MRI. To address these issues, Tijssen et al. suggest several dedicated QA tests inferring, among others, image quality at different gantry positions and image quality during beam delivery and MLC movement, which is particularly important when performing imaging during irradiation \[[@CR65]\]. Dedicated phantom set-ups and QA procedures for gated beam delivery are also subject of current research \[[@CR32], [@CR173]\].

End-to-end tests {#Sec14}
----------------

For proper end-to-end QA testing, dedicated phantoms are required. In MRgRT it is crucial that the phantom materials feature not only CT but also MRI visibility \[[@CR174], [@CR175]\] for checking all aspects of the treatment workflow, including image fusion and registration as well as potentially plan adaptation and irradiation. Moreover, dosimeters capable of accurate absolute dose measurement in 2D or even 3D in the presence of magnetic fields, e.g., film, dosimetric gel or 3D diode arrays, are required \[[@CR176]--[@CR178]\]. The use of various static and dynamic, geometrical and anthropomorphic phantoms for end-to-end tests is reported, including also dedicated end-to-end tests for stereotactic radiosurgery \[[@CR179]\] and for motion management relying on MR guidance \[[@CR173]\]. More recently, developments towards specific deformable QA phantoms are reported \[[@CR175], [@CR180]\]. Deformable phantoms are of particular interest in MRgRT, since they also enable end-to-end testing of online adaptive workflows, by altering the geometry between planning and irradiation. In addition, efforts on fast, daily end-to-end tests are discussed \[[@CR181]\]. Most of these solutions are still dedicated in-house developments and not commercially available.

Patient-specific QA {#Sec15}
-------------------

Similar to conventional radiotherapy, patient-specific QA protocols dosimetrically verifying the correct irradiation of the optimized treatment plan have been introduced in the MRgRT workflow. Due to the possibility of daily treatment adaptation, not only a single (baseline) treatment plan per patient, but several adapted plans for each patient might have to be verified. Moreover, there is the online aspect, detailed in the following subsection, related to patient-specific QA of the adapted plan prior to irradiation, while the patient is in treatment position. In general, patient-specific baseline plan QA in MRgRT can rely on phantom dose delivery and conventional dose measurement methods (multipoint IC measurement, 2D film dosimetry, quasi 3D diode arrays), similar to conventional radiotherapy \[[@CR123], [@CR182]\]. Of course, MR compatibility of dosimeters as well as of the phantoms to be used for dose measurements is crucial. In addition, protocols based solely on machine log files and either 2D fluence verification or 3D Monte Carlo-based dose reconstruction have been reported in the literature \[[@CR183]\]. In the case of online plan adaptation there is typically a fast online component and a slower offline component for the plan QA that is performed after completion of the irradiation. Werensteijn-Honingh et al. \[[@CR21]\] reported retrospective QA of the adapted plan by means of film dosimetry, while Bertelsen et al. \[[@CR184]\] relied on verification by means of a cylindrical diode array in the early clinical adoption phase. Acharya et al. instead performed an offline log-file analysis for adapted plans and only relied on measurements for the baseline plan QA \[[@CR162]\]. Also the feasibility of dose reconstruction from EPID measurements during treatment delivery has been shown and might be a future option for patient-specific offline QA of the adapted plans \[[@CR185]\].

Online adaptive workflow QA {#Sec16}
---------------------------

In addition to the described offline QA procedures, MRgRT requires specifically designed QA protocols for verifying the online adaptive radiotherapy workflow \[[@CR186]\]. The latter implies additional risks with respect to a conventional radiotherapy workflow, as procedures such as image fusion, re-contouring, plan adaptation and plan quality checks need to be performed on the fly. This translates in significant constraints for QA procedures due to limited time availability and the need to check adapted plans with the patient in treatment position \[[@CR186]\].

An example of a QA workflow for online adaptive MRgRT, including both manual and automatic checks, is depicted in Fig. [4](#Fig4){ref-type="fig"}. QA starts with checking in-room image acquisition and image fusion. The generated updated contours are verified by dedicated checklists and secondary inspection. Before plan adaptation, the correct settings for treatment plan optimization are ensured and the obtained plan is inspected, e.g., in terms of monitor units, number and shape of segments, but also under consideration of the given clinical goals \[[@CR41]\]. Eventually, patient-specific online QA of the adapted plan has to be performed. In today's clinical practice this is done by means of a secondary independent dose calculation and comparison to the treatment planning system's dose. For the secondary dose engine, usage of a fast MC-base algorithm \[[@CR40], [@CR151], [@CR162]\], but also of a collapsed-cone algorithm (not accounting for the magnetic field) has been reported \[[@CR17], [@CR21]\]. As outlined above, the adapted plans are often additionally verified retrospectively by dosimetric measurements or log-file-based dose reconstruction. Fig. 4Bottom row -- major steps of the online adaptive radiotherapy process for MRgRT. Top row -- the associated QA tasks for each step. QA tasks highlighted in orange and italic are the manual checks. QA tasks highlighted in green represent automated checks. The acronyms VRART and VRADQ refer to specific in-house developed software packages. Reprinted with permission from \[[@CR186]\]

Discussion {#Sec17}
==========

MRgRT provides unprecedented capabilities to image the patient before and online during treatment, allowing soft tissue targeting to account for inter- and intra-fractional anatomical variations. In practical clinical use, limitations exist in terms of the optimal trade-off between spatial and temporal resolution for imaging in MRgRT. There are therefore clear constraints in terms of the anatomical detail and/or the time-varying dynamics that the MR image can capture: this typically restricts pre-treatment imaging to static 3D sequences and time-resolved online imaging to single 2D planes in clinical settings. An important medical physics challenge in the near future is the development of fast time-resolved 3D-MRI sequences to improve motion monitoring and compensation in MRgRT. Research is also ongoing in the application of quantitative imaging principles to MRgRT, which would leverage even more the clinical interest in this novel IGART platform. The clinical application of MRgRT is, however, at its initial stages, and the implementation of quantitative imaging protocols will require a more consolidated use to determine the specific areas of interest. Extensive validation is required to fully explore the clinical impact of quantitative information from daily imaging in MRgRT.

Besides imaging, a key challenge in MRgRT application is the realization of dose measurements and dose calculations in the presence of a magnetic field. Conventional measurements techniques require adaption and specific calibration procedures, with a clear impact on QA protocols and medical physics involvement. For neither are dedicated guidelines yet available, driving the early MRgRT adopters to the development of dedicated in-house solutions. MRgRT also emphasizes the need for accurate and independent dose calculation engines, which calls for fast Monte Carlo implementation, as required not only for treatment plan optimization, but also for online plan verification and independent QA. The widespread use of highly efficient hardware platforms and parallel computing programming will definitely contribute to match the requirements for Monte Carlo dose calculations applicable to MRgRT.

Safe clinical adoption of MRgRT also entails unique challenges in terms of QA protocol implementation. Specifically, machine QA and end-to-end tests should, similar to dose measurements, account for the magnetic field, thus increasing the overall complexity. Dedicated tests ensuring the interference-free parallel operation of MRI and linac have to be established. In addition, online QA is required to fully exploit the imaging capabilities for treatment adaptation, with the need to define specific official protocols.

Despite these challenges, the enhanced imaging capabilities offered by MRgRT already enable routine pre-treatment plan adaption as a way to compensate for measured anatomical deviations. This represents a significant step towards more conformal treatments, as, until today, adaptation has mostly been applied via retrospective replanning imaging in reaction to measured deviations in conventional radiotherapy. While pre-treatment adaption is already routinely applied clinically in MRgRT to compensate for inter-fractional changes, intra-fractional changes, e.g., related to breathing motion, are still tackled using gating protocols due to the mentioned limitations in time-resolved imaging. The future development of fast rt-4DMRI protocols would represent an important step towards more efficient motion management by means of real-time 3D tumor and anatomy tracking in combination with real-time online plan adaptation.

Until today, target delineation, dose calculations, plan optimization and QA of the adapted plan in MRgRT contribute to considerably increase the workload with respect to conventional RT. Thus, pre-treatment plan adaptation is naturally better suited to treatments with few fractions, which is why anatomical sites where hypofractionation is indicated, such as prostate \[[@CR187]\], pancreas \[[@CR151]\], lung \[[@CR25]\], liver and adrenal gland \[[@CR188]\] as well as oligometastases \[[@CR21]\], are preferred. More details on the clinical indications for MRgRT have been recently discussed by Corradini et al. \[[@CR189]\]. Both the substantially increased workload, as well as the focus on treatment sites allowing for hypofractionated treatment, limit the routine clinical use of MRgRT. Future medical physics developments streamlining the MRgRT workflow, e.g., in terms of more accurate and robust pseudo-CT generation and improved automatic contour suggestion by means of deep learning, might play an important role to pave the way towards widespread clinical use of MRgRT.

Conclusions {#Sec18}
===========

Recent developments in MRgRT provide effective improvements in soft tissue discrimination and tumor targeting, enabling detection of anatomical changes and treatment adaptation in IGART. The ability to capture and react to inter- and intra-fractional variations is expected to improve our knowledge of dose deposition during treatment. These factors will contribute significantly to our understanding of both tumor as well as normal tissue response. Such advantages come at the price of further complexity in the implementation of effective treatment workflows, with substantial efforts for treatment QA, online evaluation and validation of potential new approaches. Nevertheless, the systematic use of MRI within an IGART workflow brings the potential of better treatment customization and evaluation of the individual treatment response.
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